This medication is commonly used to help with symptom clusters that may become intense or disruptive, specifically involuntary muscle spasm and acute localized pain. It is applied across domains where additional symptomatic support is needed for the relief of discomfort associated with acute, painful musculoskeletal conditions. This combination may provide support that assists with the experience of functional discomfort by supporting the patient during difficult episodes and by easing the impact of physical discomfort caused by heightened physiological activity.

Sodol is considered relevant in conditions characterized by periods of heightened symptoms, such as muscle strains, acute back discomfort, and neck tension involving significant muscular tension. It is applied in clinical settings that involve acute or unstable symptom patterns, where short-term symptomatic assistance is needed. This supportive relief may contribute to easing the overall symptom load during these periods, and may help patients cope more steadily with symptom fluctuations when symptoms are more noticeable.

---

“It is typically used in situations involving certain distressing symptoms of the muscles where short-term symptomatic assistance is appropriate.”

---

Quick Fact: Relief Focus	Description
Primary Symptoms	Muscle Spasm, Acute Localized Pain
Typical Condition	Acute Musculoskeletal Strains
Goal of Use	Symptomatic support during recovery
Patient Benefit	Supports patients during episodes of heightened discomfort

Regulatory References

1. NIH DailyMed overview

Who Can and Cannot Use Sodol?

Eligibility to use Sodol (Carisoprodol and Acetylsalicylic Acid) is strictly defined by government regulatory documents, focusing on patient status and history.

Contraindications and Prohibited Use

Sodol is contraindicated and must not be used by specific patient groups. This includes individuals with a history of acute intermittent porphyria, those with known hypersensitivity to carisoprodol, aspirin, or any carbamate derivatives, and patients with aspirin-induced asthma.

Additionally, use is prohibited during the last three months of pregnancy and in patients who have a history of a serious gastrointestinal complication (such as bleeding or perforation) related to aspirin use.

Population Restrictions and Conditional Use

Population Group	Regulatory Status
Pediatric Patients (<12)	Safety and effectiveness have not been established
Geriatric Patients (≥65)	Safety and efficacy have not been established; use with caution
Hepatic or Renal Impairment	Use with caution is required
Lactating/Nursing Mothers	Not recommended due to potential serious effects on the infant

Sodol is primarily indicated for use in adults who are otherwise eligible. Regulatory labeling advises caution for patients with a history of drug abuse/dependence and those with metabolic or pre-existing gastrointestinal conditions like gastritis or peptic ulcers.

Sodol (Acetylsalicylic Acid and Carisoprodol) has officially documented interaction patterns primarily involving pharmacodynamic reinforcement and pharmacokinetic alteration. Co-administration with CYP2C19 inhibitors is documented to result in an increased systemic exposure (AUC) of Carisoprodol and reduced exposure to its metabolite, Meprobamate. This pharmacokinetic interaction is of heightened significance for individuals classified as CYP2C19 Poor Metabolizers, who naturally exhibit significantly altered drug levels as described in regulatory labeling.

Pharmacodynamically, Sodol interacts with Alcohol (Ethanol) and other CNS depressants (such as Opioids and Benzodiazepines), producing an officially noted additive sedative effect that can impair physical and mental function. The Acetylsalicylic Acid component introduces interactions with Anticoagulants and Antiplatelet Agents, officially increasing the risk of bleeding by interfering with platelet function and prothrombin concentration. Interactions are additionally noted with certain Herbal Products (e.g., Ginger, Ginkgo biloba) that may share antiplatelet properties.

Certain combinations are classified as restricted or contraindicated in regulatory labeling. This includes co-administration with Defibrotide, Ketorolac, and Cidofovir. High-dose Acetylsalicylic Acid co-administration with Methotrexate is also restricted due to the documented potential for enhanced toxicity. The official regulatory profile defines these conditions and substance classes where the drug's exposure or effect is officially modified.

Sodol exerts its effects via a dual pharmacodynamic profile, engaging two distinct molecular domains to modulate cardiac electrophysiology.

Mechanism 1: Class III Antiarrhythmic Activity

The drug functions as an inhibitor of the rapid delayed-rectifier potassium current ( I Kr) in myocardial tissue. This interaction specifically blocks the associated potassium channels, leading to a prolongation of the action potential duration, primarily during the repolarization phase. Consequently, the effective refractory period is extended within both the atrium and ventricle, which modifies the excitability and conductivity of the cardiac electrical circuit.

Mechanism 2: Class II Antiarrhythmic Activity

Sodol simultaneously acts as a non-selective antagonist at both beta1- and beta2-adrenergic receptors. By competitively binding to these receptors, the drug prevents their activation by endogenous catecholamines. This antagonism reduces sympathetic drive on the heart, resulting in decreased spontaneous discharge of the sinus node, slowed conduction through the atrioventricular ( AV) node, and reduced myocardial oxygen demand.

How to Use Sodol: Official Administration Guidelines

Sodol is an oral fixed-dose combination tablet intended for short-term administration only. The official usage guidelines define the route, dosing, frequency, and maximum duration.

---

Administration Principles

The standard adult usage pattern involves taking 1 to 2 tablets per dose, administered four times a day (q.i.d.), with the total daily intake strictly limited to 8 tablets. This regimen is designed for a short treatment period, typically confined to a maximum of two or three weeks.

Administration of the tablet is oral and may occur with or without food. Regardless of meal timing, the tablet should be swallowed with a full glass of water to facilitate proper use. To manage administration conditions, the individual is generally advised to remain in an upright position for at least 10 minutes following ingestion.

---

Population-Specific Usage

Usage rules are modified for certain patient groups. Sodol is not recommended for individuals under 16 years of age. For older adults, the official guidance suggests that dose selection should be cautious, generally favoring a starting dose at the lower end of the established range. Similar caution is advised when using the medicine in patients with known hepatic or renal impairment.

---

Use Protocol Summary

The administration protocol defines a time-bound course of therapy taken four times daily, restricted to a maximum of three weeks. This structure is intended solely for acute symptomatic periods, as established for this therapeutic regimen.

Research evidence / Overview of Studies for Sodol

This overview summarizes the type of research that was studied for the fixed-dose combination of Carisoprodol and Acetylsalicylic Acid (Sodol), focusing on what the studies explored and what aspects of the medicine’s use are still uncertain according to the scientific record.

---

Evidence for Use in Acute Musculoskeletal Discomfort

The evidence base for Sodol consists primarily of short-term, randomized, controlled clinical trials (RCTs) and findings related to its individual components. The research examined the combination’s role was studied for adjunct use in acute, painful conditions associated with muscle spasm, such as acute back discomfort. These studies focused on research scenarios where symptoms may vary in intensity, examining patient-reported outcomes describing perceived discomfort over defined, short time intervals.

In these trials, researchers monitored outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort. The evidence level related to the combination in acute settings is classified as Moderate. This classification reflects that while clinical trials exist, the research describes situations where evidence quality varies across studies, and the certainty for broad application remains low. Research provides context but not individual predictions, as findings describe group patterns, not personal outcomes.

---

Durability of Effect and Long-Term Follow-up Data

The key clinical research scenarios studies monitored patient responses over strictly defined and limited time intervals, with typical follow-up periods being seven to fourteen days. Due to this study design, the follow-up durations were limited.

Regulatory agencies have stated that adequate evidence of outcomes for use beyond two to three weeks is not established in the research record. Therefore, there is limited information for long-term outcomes, and the durability of any observed response remains not well characterized by the existing studies.

---

Research Findings in Specific Patient Groups

The research focused on outcomes for Sodol was observed in adults between 18 and 64 years of age. The results apply only to the populations studied, and data for certain groups remain insufficient.

Limited data are available concerning the use of Sodol in older adults (aged 65 and older) or in pediatric patients (under 16 years of age). Therefore, the existing studies provide limited insight into the specific outcomes or patterns of use for these particular subgroups.

---

Key Limitations and Areas of Uncertainty in the Evidence

The most significant limitation is the absence of adequate long-term data. Because the follow-up durations were limited, the long-term effects are not fully established. Additionally, the sample sizes were modest in some trials, and comparative evidence is lacking for certain fixed-dose combination questions. These limitations describe where the research provides context, while highlighting areas where comprehensive data are still limited.

Key Studies & References Official Prescribing Information for Carisoprodol and Aspirin Tablets (DailyMed)

Common questions about Sodol (FAQ)

---

Q: Can Sodol cause stomach bleeding?

Official prescribing information states that Sodol contains acetylsalicylic acid, an NSAID component associated with serious gastrointestinal adverse events. These events can include inflammation, ulceration, and bleeding in the stomach or intestines. The official product information states this risk may be life-threatening and can occur without obvious warning signs.

---

Q: Does Sodol contain aspirin?

Yes, Sodol is a fixed-dose combination tablet containing two active ingredients: Carisoprodol and Acetylsalicylic Acid (ASA). Acetylsalicylic Acid is the chemical name for the common drug known as aspirin. This blend provides both muscle relaxation and general pain relief.

---

Q: What do I do with old or unused Sodol tablets?

Regulatory guidance suggests that unused or expired tablets should preferably be disposed of through an authorized drug take-back program. If a take-back program is not accessible, the medicine should be removed from its container, mixed with an undesirable substance (like dirt or coffee grounds), and placed in a sealed bag or container before disposal in the household trash. It is explicitly required not to flush Sodol down a sink or toilet.

---

Q: Is Sodol a controlled substance?

Yes. According to official classification, the Carisoprodol component of Sodol is designated as a Schedule IV controlled substance in the United States. All federal regulations concerning controlled substances apply to the proper handling, storage, and dispensing of this product.

---

Q: What should I do if I miss a dose of Sodol?

If a dose is missed, regulatory information suggests it may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, official guidance states that the missed dose should be skipped and the regular schedule resumed. Official guidance states that double doses should not be taken to compensate for a missed dose.

---

Q: How long does it take for Sodol to start working?

Pharmacokinetic studies indicate that the active ingredient carisoprodol is rapidly absorbed after administration. The maximum concentration of the drug in the blood is reached in approximately 1.7 to 2.0 hours following a single oral dose.

---

Q: How does Sodol work to relieve muscle spasms?

Official information explains that the precise way the carisoprodol component relieves muscle discomfort is not clearly established. It is classified as a centrally acting muscle relaxant, meaning it affects the central nervous system rather than directly relaxing skeletal muscles. Its effects are not entirely understood, and the muscle relaxing properties may be related to its known sedative effects.

How to Store and Dispose of Sodol

Storage and disposal must strictly adhere to regulatory labeling to maintain product quality and ensure safety.

---

Storage Requirements

Sodol tablets must be stored at Controlled Room Temperature, specifically between 15 C and 30 C (59 F to 86 F). The product must be protected from both moisture and freezing and kept in a dry place. It is required to store the tablets in the original container with the lid tightly closed. Due to the presence of a controlled substance, all tablets must be stored securely out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Sodol should preferably be disposed of through a drug take-back program. If a take-back program is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (such as coffee grounds or dirt), sealed in a bag or container, and then placed in the household trash. It is explicitly required not to dispose of the product by flushing down a sink or toilet.